Chembio Diagnostics (CEMI) to Offer Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq set to open higher as AI stocks rebound ahead of earnings rush
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month high with Hormuz transits in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- S&P 500, Nasdaq set to open higher as AI stocks rebound ahead of earnings rush
- Microsoft pulls out of UK data center deal with Nscale, Telegraph reports
- AST SpaceMobile partners with four European operators on MSS spectrum
- Lithuanians forced to take shelter after suspected drone enters airspace
Chembio Diagnostics Announces Proposed Public Offering of Common Stock
May 6, 2020 4:01 PM EDTHAUPPAUGE, N.Y., May 06, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) (Chembio), a leading point-of-care diagnostic company focused on infectious diseases, announced today a proposed public offering of an undetermined number of shares of its common stock. All shares of common stock to be sold in the proposed offering will be offered by Chembio. In addition, Chembio expects to grant the underwriters a 30-day option to purchase additional shares, in a number equal to up to 15% of the number of shares of common stock sold in the proposed offering, at the public offering price less the underwriting... More



